Skip to main content
. 2018 Apr 18;29(4):e63. doi: 10.3802/jgo.2018.29.e63

Table 1. Patient and clinical characteristics.

Characteristics Group 1 (n=216) Group 2 (n=219) p
Age (yr) 56 (22–83) 55 (26–79) 0.779
BMI (kg/m2) 22.9 (16.0–40.3) 22.5 (16.4–34.4) 0.530
FIGO stage <0.001
III 152 (70.4) 93 (42.5)
IV 64 (29.6) 126 (57.5)
Tumor grade 0.214
1 16 (7.4) 11 (5.0)
2 72 (33.4) 62 (28.3)
3 107 (49.5) 113 (51.6)
Not available 21 (9.7) 33 (15.1)
Histologic type 0.696
Serous 174 (80.6) 179 (82.1)
Endometrioid 10 (4.6) 5 (2.3)
Mucinous 14 (6.5) 14 (6.4)
Clear cell 9 (4.2) 12 (5.5)
Other 9 (4.2) 9 (3.7)
ASA score <0.001
1 128 (59.3) 60 (27.4)
2 77 (35.6) 110 (50.2)
3 5 (2.3) 42 (19.2)
4 0 (0) 1 (0.5)
Not available 6 (2.8) 6 (2.7)
Median CA-125 level (U/mL) 897.1 (8.7–30,008.8) 1,474.1 (12.9–30,000.0) 0.003
NAC <0.001
Yes 35 (16.2) 107 (48.9)
No 181 (83.8) 112 (51.1)
Chemotherapy regimen 0.006
Paclitaxel+carboplatin 156 (72.2) 171 (78.1)
Docetaxel+carboplatin 25 (11.6) 36 (16.4)
Paclitaxel+carboplatin+bevacizumab 1 (0.5) 3 (1.4)
Paclitaxel+cisplatin 2 (0.9) 3 (1.4)
IP chemotherapy 28 (13.0) 0 (0)
Others 2 (0.9) 2 (0.9)
Not available 2 (0.9) 4 (1.8)
Cycles of total chemotherapy 0.005
≤6 158 (73.1) 132 (60.3)
>6 58 (26.9) 87 (39.7)

Values are presented as median (range) or number (%).

ASA, American Society of Anesthesiologists; BMI, body mass index; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; IP, intraperitoneal; NAC, neoadjuvant chemotherapy.